Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Operating activities
Net loss	$ (75,975)	$ (12,828)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	647	469
Stock-based compensation	6,441	44
Non-cash research and development expenses	20,000
Non-cash lease expense	604	365
Non-cash loss from equity method investment in joint venture	50
Changes in fair value of derivative liability	6,231
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(2,444)	(13)
Accounts payable	4,643	558
Accrued expenses and other current liabilities	5,092	1,742
Operating lease liabilities	(615)	(421)
Net cash used in operating activities	(35,326)	(10,084)
Investing activities
Purchase of property and equipment	(540)	(1,483)
Investment in joint venture	(50)
Net cash used in investing activities	(590)	(1,483)
Financing activities
Proceeds from issuance of Series B convertible preferred stock, net of issuance costs	151,581
Proceeds from issuance of common stock in initial public offering, net of issuance costs	152,296
Proceeds From Issuance Of Common Stock		3
Proceeds from the exercise of stock options	167	32
Net cash provided by financing activities	304,044	35
Net increase (decrease) in cash, cash equivalents, and restricted cash	268,128	(11,532)
Cash, cash equivalents and restricted cash at beginning of year	8,188	19,720
Cash, cash equivalents and restricted cash at end of year	276,316	8,188
Supplemental schedule of noncash operating and financing activities:
Purchases of property and equipment in accounts payable and accrued expenses	11	28
Operating lease right-of-use asset obtained in exchange for new operating lease liabilities		1,186
Reconciliation of cash, cash equivalents and restricted cash:
Cash and cash equivalents	274,735	8,080
Restricted cash	1,581	108
Total cash, cash equivalents and restricted cash shown in the statement of cash flows	$ 276,316	$ 8,188